Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
2 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
29 Mar 22
Current reports
8-K
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jul 23
8-K
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
11 Jul 23
8-K
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
12 May 23
8-K
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
30 Mar 23
Registration and prospectus
424B3
Prospectus supplement
28 Mar 24
424B3
Prospectus supplement
9 Aug 22
S-8
Registration of securities for employees
29 Mar 22
424B5
Prospectus supplement for primary offering
17 Dec 21
D
$19.63M in options / securities to be acquired, sold $45K, 5 investors
20 Jul 21
S-3
Shelf registration
26 May 21
D
$3.25M in options / securities to be acquired, 5 investors
23 Feb 21
424B5
Prospectus supplement for primary offering
16 Feb 21
S-8
Registration of securities for employees
26 Jan 21
424B3
Prospectus supplement
14 Aug 20
Proxies
DEF 14A
Definitive proxy
2 Jun 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
1 Feb 22
DEFA14A
Additional proxy soliciting materials
30 Dec 21
DEF 14A
Definitive proxy
30 Dec 21
PRE 14A
Preliminary proxy
20 Dec 21
DEFA14A
Additional proxy soliciting materials
17 Dec 21
DEFA14A
Additional proxy soliciting materials
17 Dec 21
DEFA14A
Additional proxy soliciting materials
15 Dec 21
Other
EFFECT
Notice of effectiveness
10 Jun 21
CORRESP
Correspondence with SEC
7 Jun 21
UPLOAD
Letter from SEC
7 Jun 21
EFFECT
Notice of effectiveness
14 Aug 20
CORRESP
Correspondence with SEC
11 Aug 20
UPLOAD
Letter from SEC
11 Aug 20
EFFECT
Notice of effectiveness
6 Jul 20
CORRESP
Correspondence with SEC
1 Jul 20
UPLOAD
Letter from SEC
1 Jul 20
EFFECT
Notice of effectiveness
11 Apr 19
Ownership
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Michelle Siegert
30 Jan 23
4
Margaret Wasilewski
30 Jan 23
4
Teofilo David Raad
30 Jan 23
4
Todd Bazemore
30 Jan 23
4
Michael J Higgins
30 Jan 23
4
Christopher Cabell
30 Jan 23
4
Anand Varadan
30 Jan 23
4
Richard P. Batycky
30 Jan 23